MX9203263A - Composicion farmaceutica analgesica para administracion nasal. - Google Patents

Composicion farmaceutica analgesica para administracion nasal.

Info

Publication number
MX9203263A
MX9203263A MX9203263A MX9203263A MX9203263A MX 9203263 A MX9203263 A MX 9203263A MX 9203263 A MX9203263 A MX 9203263A MX 9203263 A MX9203263 A MX 9203263A MX 9203263 A MX9203263 A MX 9203263A
Authority
MX
Mexico
Prior art keywords
analgesical
pharmaceutical composition
nasal administration
nasal
administration
Prior art date
Application number
MX9203263A
Other languages
English (en)
Inventor
Anwar A Hussain
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of MX9203263A publication Critical patent/MX9203263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX9203263A 1981-04-28 1992-06-24 Composicion farmaceutica analgesica para administracion nasal. MX9203263A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/258,308 US4464378A (en) 1981-04-28 1981-04-28 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same

Publications (1)

Publication Number Publication Date
MX9203263A true MX9203263A (es) 1992-07-01

Family

ID=22980011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203263A MX9203263A (es) 1981-04-28 1992-06-24 Composicion farmaceutica analgesica para administracion nasal.

Country Status (5)

Country Link
US (1) US4464378A (es)
EP (1) EP0077393A1 (es)
CA (1) CA1183778A (es)
MX (1) MX9203263A (es)
WO (1) WO1982003768A1 (es)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR71929B (es) * 1979-11-13 1983-08-19 Ici Ltd
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4973596A (en) * 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
DE3939376C1 (es) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
WO1993014727A1 (en) * 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
DE69427551T2 (de) * 1993-03-15 2002-05-16 Nat Science Council Taipeh T A Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
EP0721348B1 (en) * 1993-09-29 1999-09-01 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
DE19536244A1 (de) * 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung zur lokalen Applikation
US5866143A (en) * 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US7220737B1 (en) * 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
EP2338494B1 (en) * 1997-09-04 2013-07-10 DemeRx, Inc. Noribogaine in the treatment of pain and drug addiction
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CN1234362C (zh) 1997-12-22 2006-01-04 欧罗赛铁克股份有限公司 阿片样激动剂/阿片样拮抗剂组合物
TR200001828T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE69917000T2 (de) 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
AU766988B2 (en) * 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
AU6046900A (en) * 1999-06-16 2001-01-02 Nastech Pharmaceutical Company, Inc Method for increasing the solubility of morphine and pharmaceutical compositionsprepared therefrom
BR0012082A (pt) * 1999-06-16 2002-05-07 Nastech Pharm Co Formulação farmacêutica para administração compreendendo morfina e seu uso
CZ2002728A3 (cs) 1999-08-27 2002-08-14 Southern Research Institute Prostředek ve formě mikročástic obsahující buprenorfin, léková forma a pouľití
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20020034534A1 (en) * 1999-12-16 2002-03-21 Barr Deborah P. System and method for delivering a therapeutic agent over an extended period of time in conjuction with a receptor loading dose of the therapeutic agent
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1255547B1 (en) 2000-02-08 2008-08-20 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
JP2003534298A (ja) 2000-05-23 2003-11-18 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 咳の新規治療法
CA2411564A1 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
CN101181241A (zh) 2000-07-31 2008-05-21 尼科梅德丹麦股份有限公司 用于鼻内给药的芬太尼组合物
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2713502A (en) 2000-10-31 2002-05-15 Rensselaer Polytech Inst 8-carboxamido-2,6-methano-3-benzazocines
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1416842B1 (en) 2001-07-18 2008-12-31 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CN1652766A (zh) * 2002-03-18 2005-08-10 免疫力药品有限公司 间苯二酚和大麻素的局部制剂及其施用方法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
MXPA04010612A (es) 2002-04-23 2005-07-14 Alza Corp Sistemas analgesicos transdermicos con potencial reducido de abuso.
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2359977T3 (es) 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
EP2184058B1 (en) * 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
EP2269606A3 (en) * 2003-10-30 2012-04-25 ALZA Corporation Transdermal analgesic systems having reduced abuse potential
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006063109A2 (en) 2004-12-09 2006-06-15 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
DK1895994T3 (da) * 2005-05-13 2010-12-20 Alza Corp Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
EP2179741B1 (en) * 2005-08-26 2014-10-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administraton of oxytocin
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
EP1810669A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Darreichungsform für Buprenorphin
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK3045043T3 (da) * 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20110092532A1 (en) * 2009-10-16 2011-04-21 John Todhunter Apomorphine pharmaceutical dosage security system
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
FR2963889B1 (fr) 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
BR112013029126A2 (pt) 2011-05-13 2017-02-07 Euro Celtique Sa formas de dosagem farmacêuticas intranasais compreendendo naloxona
HUE034326T2 (en) 2011-06-29 2018-02-28 Alkermes Inc Peripheral acting opioid compounds
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2692771T3 (es) 2011-12-15 2018-12-05 Alkermes Pharma Ireland Limited Samidorfano (ALKS 33) en combinación con buprenorfina para el tratamiento de trastornos depresivos
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
WO2014016653A1 (en) 2012-07-26 2014-01-30 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
GB2538682B (en) 2014-03-14 2017-12-13 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
CA2989550C (en) 2014-06-18 2023-08-08 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
ES2963707T3 (es) 2015-01-07 2024-04-01 Tonix Pharma Ltd Formulaciones de oxitocina que contienen magnesio y métodos de uso
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
RU2769397C2 (ru) 2016-11-18 2022-03-31 Опиант Фармасьютикалз, Инк. Композиции и способы лечения передозировки опиоидами
US10356931B1 (en) 2017-05-26 2019-07-16 King Slide Works Co., Ltd. Rack mounting system
US20200345655A1 (en) * 2017-11-15 2020-11-05 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition

Also Published As

Publication number Publication date
CA1183778A (en) 1985-03-12
WO1982003768A1 (en) 1982-11-11
US4464378A (en) 1984-08-07
EP0077393A1 (en) 1983-04-27

Similar Documents

Publication Publication Date Title
MX9203263A (es) Composicion farmaceutica analgesica para administracion nasal.
MX9101175A (es) Composicion farmaceutica para administracion nasal
GB2100605B (en) Bandage for administering drugs.
ATE22007T1 (de) Pharmazeutische mischung.
IT8220611A0 (it) Composizioni farmaceutiche topiche.
FI822005A0 (fi) Antifungisida aemnen, foerfarande foer deras framstaellning, och dessa innehaollande farmaceutiska sammansaettningar
IT8619625A0 (it) Composizioni farmaceutiche per inalazione.
DE3485408D1 (de) Pharmazeutische zusammensetzung.
FI822670L (fi) Ergopeptinderivat, foerfaranden foer deras framstaellning, dessa innehaollande farmaceutiska kompositioner och deras anvaendning vid terapeutisk behandling
DE3382112D1 (de) Pharmazeutische zusammensetzung.
FI823544L (fi) Triazinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar
IT8248677A0 (it) Formulazioni farmaceutiche
IT1213453B (it) Composizione farmaceutica.
ATE36455T1 (de) Pharmazeutische zusammensetzungen.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
NO830294L (no) Medikamentinhalator.
NL193821B (nl) Farmaceutisch preparaat.
MX9202984A (es) Composiciones farmaceuticas que contienen salbutamol.
IT8124920A0 (it) Nuova composizione farmaceutica.
FI823470L (fi) Nya cykliska iminer, deras tillverkning och farmaceutiska kompositioner innehaollande dessa
FI830462L (fi) Mjoeldrygealkaloider, foerfarande foer deras framstaellning och dessa foereningar innehaollande farmaceutiska kompositioner
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
FI823694A0 (fi) N-substituerade ergolin- och 9,10,-didehydro-ergolin-8-karboxiamid-8-aminometyl-derivat, deras framstaellning och deras farmaceutiska komposition
IT8224219A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.
IT8222757A0 (it) Composizione farmaceutica antiateromasica.